用于治疗超静脉性鼻结功能障碍的心脏神经移除
Arshneel Kochar1, Tyler Taigen1, Jeffery Courson1
1Department of Pacing and Electrophysiology, Cleveland Clinic, Cleveland, Ohio, USA.
JACC. Case reports
|February 21, 2024
概括
超静脉性鼻节功能障碍,由于高阴道音调导致心率缓慢的特征,现在可以通过心脏神经衰竭治疗. 这种创新的程序为有症状的患者提供了心脏起器的替代方案.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 自主神经系统的自主神经系统
背景情况:
- 节功能障碍 (SND) 包含各种心律障碍.
- 超静脉性SND特别与过度的阴道神经活动有关,导致胸肌梗塞.
- 目前对症状患者的治疗往往需要植入心脏起器.
研究的目的:
- 引入心脏神经衰竭作为超流性SND的新型治疗方法.
- 探索一种超越传统心脏起器植入的替代治疗选择.
主要方法:
- 该研究描述了心脏神经衰竭手术的过程.
- 诊断超静脉性SND的支持是对氨酸的反应,它解决了胸肌梗塞.
- 介绍了接受该程序的患者的病例描述.
主要成果:
- 心脏神经衰变被认为是对高静脉性SND的可行的治疗方法.
- 该程序为因高阴道度而患有胸肌梗塞的患者提供了潜在的解决方案.
结论:
- 心脏神经移除代表了在管理超静脉性SND方面取得的重大进展.
- 这种技术为有症状的个体提供了一种新的治疗途径,可能减少对起器的依赖.
相关概念视频
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias
215
Arrhythmias are disturbances in the heart's rhythm that lead to abnormal heartbeats. These irregularities can originate from different parts of the heart and are classified based on their origin and nature.
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
215
Disturbances in Heart Rhythm
956
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
956
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
744
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
744
Electrophysiology of Normal Cardiac Rhythm
4.3K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
4.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431


